{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:37:54Z","timestamp":1787009874030,"version":"build-2736575974"},"reference-count":93,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Immune check point inhibitors (ICIs) are a unique class of cancer treatments that harness the body's innate antitumor response. Although these medications have transformed oncology care, they also lead to generalized immune activation that can result in toxicities across a spectrum of organ systems called immune-related adverse events. This article reviews the most common rheumatologic immune-related adverse events and their management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Inflammatory arthritis, polymyalgia rheumatic, sicca symptoms, systemic sclerosis, myositis, and vasculitis have all been reported as ICI adverse events. Treatment includes nonsteroidal anti-inflammatory drugs, glucocorticoids, traditional DMARDs, and biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Rheumatologists have an important role in the management of patients with rheumatologic immune-related adverse events. Working with our oncology colleagues, we can help manage rheumatologic immune-related adverse events while optimally preserving ICI's antitumor effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/bor.0000000000000935","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T06:02:31Z","timestamp":1678687351000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Rheumatologic immune checkpoint inhibitor-related adverse events"],"prefix":"10.1097","volume":"35","author":[{"given":"Melissa","family":"Defoe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie L.","family":"Bermas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.mayocp.2019.03.012","article-title":"Immune checkpoint inhibitor toxicities","volume":"94","author":"Marin-Acevedo","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fmed.2019.00119","article-title":"Biomarkers for immune checkpoint inhibitor-mediated tumor response and adverse events","volume":"6","author":"Nakamura","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","article-title":"Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review","volume":"64","author":"Khan","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors \u2013 a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"9139","DOI":"10.2147\/CMAR.S218756","article-title":"Management of immune checkpoint inhibitor toxicities","volume":"12","author":"Durrechou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in Stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"vii68","DOI":"10.1093\/rheumatology\/kez295","article-title":"Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy","volume":"58","author":"Kostine","year":"2019","journal-title":"Rheumatology (United Kingdom)"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semcancer.2019.01.006","article-title":"Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis","volume":"64","author":"Kumar","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s11912-018-0718-6","article-title":"Immune checkpoint inhibitor toxicity","volume":"20","author":"Palmieri","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"(22 Pt 1)","key":"R17-20250526","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors","volume":"22","author":"Judd","year":"2017","journal-title":"Oncologist"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"(Suppl 7)","key":"R20-20250526","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology (Oxford, England)"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/BOR.0000000000000672","article-title":"Immune checkpoint inhibitors and vasculitis","volume":"32","author":"Boland","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/1744666X.2020.1804362","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management","volume":"16","author":"Williams","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/BOR.0000000000000701","article-title":"Treatment of immune checkpoint inhibitor-induced inflammatory arthritis","volume":"32","author":"Jeurling","year":"2020","journal-title":"Curr Opin Rheumatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"e000714","DOI":"10.1136\/rmdopen-2018-000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","journal-title":"RMD open"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/art.41036","article-title":"A rare side effect of checkpoint inhibitor therapy-nivolumab-induced axial polyarthritis of the facet and costovertebral joints","volume":"71","author":"Feist","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.40043","article-title":"Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of cancer","volume":"69","author":"Suarez-Almazor","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/BOR.0000000000000601","article-title":"Arthritis risk with immune checkpoint inhibitor therapy for cancer","volume":"31","author":"Pundole","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.lungcan.2017.04.007","article-title":"Development of psoriatic arthritis during nivolumab therapy for metastatic nonsmall cell lung cancer, clinical outcome analysis and review of the literature","volume":"108","author":"Ruiz-Ba\u00f1obre","year":"2017","journal-title":"Lung Cancer"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","article-title":"Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer","volume":"55","author":"Law-Ping-Man","year":"2016","journal-title":"Rheumatology (United Kingdom)"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-programmed cell death 1\/anti-programmed cell death-ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"le Burel","year":"2017","journal-title":"Eur J Cancer"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.currproblcancer.2017.10.003","article-title":"Anti-PD1\/PDL1 induced psoriasis","volume":"41","author":"Voudouri","year":"2017","journal-title":"Curr Probl Cancer"},{"key":"R35-20250526","first-page":"182","article-title":"Psoriatic arthritis due to nivolumab administration a case report and review of the literature","volume":"23","author":"Sapalidis","year":"2018","journal-title":"Respir Med Case Rep"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1177\/1078155219884113","article-title":"Pembrolizumab- and\/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma","volume":"26","author":"Bas","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1111\/1346-8138.13840","article-title":"Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma","volume":"44","author":"Wada","year":"2017","journal-title":"J Dermatol"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13256-018-1579-1","article-title":"Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report","volume":"12","author":"Ngo","year":"2018","journal-title":"J Med Case Rep"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.semarthrit.2017.03.003","article-title":"Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab","volume":"47","author":"Gauci","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.23467","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","article-title":"Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series","volume":"76","author":"Kim","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2018.09.027","article-title":"Rheumatic immune-related adverse events secondary to anti\u2013programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on antitumour response: a case series","volume":"105","author":"Mitchell","year":"2018","journal-title":"Eur J Cancer"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.semarthrit.2018.10.012","article-title":"Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: a single center experience","volume":"48","author":"Mooradian","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"e238851","DOI":"10.1136\/bcr-2020-238851","article-title":"First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis","volume":"14","author":"Murray","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s10067-019-04451-2","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor\u2013induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","journal-title":"Clin Rheumatol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejim.2021.07.016","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","journal-title":"Eur J Intern Med"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5070\/D3238036018","article-title":"A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy","volume":"23","author":"Elosua-Gonz\u00e1lez","year":"2017","journal-title":"Dermatol Online J"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"e102","DOI":"10.1016\/j.jtho.2018.01.027","article-title":"Atezolizumab after nivolumab-induced inflammatory polyarthritis: can anti-PD-L1 immunotherapy be administered after anti-PD-1-related immune toxicities?","volume":"13","author":"Swami","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jdcr.2021.03.015","article-title":"Apremilast for immune checkpoint inhibitor-induced psoriasis: a case series","volume":"11","author":"Mayor Ibarguren","year":"2021","journal-title":"JAAD case reports"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMc1703047","article-title":"Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade","volume":"376","author":"Esfahani","year":"2017","journal-title":"N Engl J Med"},{"key":"R54-20250526","first-page":"e5824","article-title":"A novel approach to the treatment of pembrolizumab-induced psoriasis exacerbation: a case report","volume":"11","author":"Monsour","year":"2019","journal-title":"Cureus"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00296-020-04665-7","article-title":"Immune checkpoint inhibitor-induced musculoskeletal manifestations","volume":"41","author":"Angelopoulou","year":"2021","journal-title":"Rheumatol Int"},{"key":"R56-20250526","first-page":"68","article-title":"Identification and classification of polymyalgia rheumatica (PMR) and PMR-like syndromes following immune checkpoint inhibitors (ICIs) therapy: discussion points and grey areas emerging from a systematic review of published literature","volume":"7","author":"Manzo","year":"2020","journal-title":"Medicines (Basel)"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"e000906","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.3390\/ijms21093389","article-title":"Rheumatic manifestations in patients treated with immune checkpoint inhibitors","volume":"21","author":"Melissaropoulos","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1136\/annrheumdis-2020-217225","article-title":"Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy","volume":"81","author":"Martin de Fremont","year":"2020","journal-title":"Ann Rheum Dis Month"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1136\/annrheumdis-2020-218276","article-title":"Management of immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"81","author":"van der Geest","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1634\/theoncologist.2018-0823","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","journal-title":"Oncologist"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/odi.14000","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"28","author":"Harris","year":"2022","journal-title":"Oral Dis"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"e00322","DOI":"10.1002\/rcr2.322","article-title":"Nivolumab-induced sialadenitis","volume":"6","author":"Takahashi","year":"2018","journal-title":"Respirol Case Rep"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s40425-018-0429-4","article-title":"A severe case of neuro-Sj\u00f6gren's syndrome induced by pembrolizumab","volume":"6","author":"Ghosn","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.clim.2020.108497","article-title":"Sicca syndrome following immune checkpoint inhibition","volume":"217","author":"Mavragani","year":"2020","journal-title":"Clin Immunol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1634\/theoncologist.2019-0467","article-title":"Sicca syndrome induced by immune checkpoint inhibitor therapy: optimal management still pending","volume":"25","author":"Ortiz Brugu\u00e9s","year":"2020","journal-title":"Oncologist"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/rheumatology\/kez242","article-title":"Hydroxychloroquine treatment downregulates systemic interferon activation in primary Sj\u00f6gren's syndrome in the JOQUER randomized trial","volume":"59","author":"Bodewes","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review","volume":"21","author":"Kadota","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"R73-20250526","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.3390\/ijms21093054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"(S2)","key":"R74-20250526","first-page":"S74","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripheral Nerv Syst"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R76-20250526","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated antistriated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R77-20250526","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.semarthrit.2018.05.006","article-title":"Myositis as an adverse event of immune checkpoint blockade for cancer therapy","volume":"48","author":"Shah","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R78-20250526","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","article-title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","volume":"31","author":"Doms","year":"2020","journal-title":"Ann Oncol"},{"key":"R79-20250526","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/CIRCULATIONAHA.120.052307","article-title":"Mending broken hearts: a new treatment paradigm for immune checkpoint inhibitor-induced myocarditis","volume":"143","author":"Bermas","year":"2021","journal-title":"Circulation"},{"key":"R80-20250526","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"R81-20250526","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaad.2020.09.054","article-title":"Cutaneous adverse events caused by immune checkpoint inhibitors","volume":"85","author":"Quach","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R82-20250526","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/cup.13273","article-title":"Scleroderma-like skin changes induced by checkpoint inhibitor therapy","volume":"45","author":"Tjarks","year":"2018","journal-title":"J Cutan Pathol"},{"key":"R83-20250526","doi-asserted-by":"crossref","first-page":"e000750","DOI":"10.1136\/jitc-2020-000750","article-title":"Checkpoint inhibitor-related renal vasculitis and use of rituximab","volume":"8","author":"Mamlouk","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R84-20250526","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","article-title":"Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition","volume":"55","author":"van den Brom","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R85-20250526","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors\u2014a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"R86-20250526","doi-asserted-by":"crossref","first-page":"e233496","DOI":"10.1136\/bcr-2019-233496","article-title":"Immune checkpoint inhibitor induced large vessel vasculitis","volume":"13","author":"Henderson","year":"2020","journal-title":"BMJ Case Reports"},{"key":"R87-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5152\/eurjrheum.2019.19061","article-title":"Isolated testicular vasculitis due to immune checkpoint inhibitor","volume":"7","author":"Weiner","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"R88-20250526","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.ejim.2018.07.023","article-title":"Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: a case series","volume":"57","author":"Tomelleri","year":"2018","journal-title":"Eur J Intern Med"},{"key":"R89-20250526","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"R90-20250526","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.euf.2019.04.014","article-title":"Rare, but severe: vasculitis and checkpoint inhibitors","volume":"6","author":"Lindner","year":"2020","journal-title":"Eur Urol Focus"},{"key":"R91-20250526","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jdcr.2018.03.013","article-title":"Nivolumab-induced systemic vasculitis","volume":"4","author":"Kang","year":"2018","journal-title":"JAAD Case Rep"},{"key":"R92-20250526","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"R93-20250526","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000935","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T17:19:41Z","timestamp":1748279981000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000935","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}